<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Keystone, Edward</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Reflex Study: Prevention of Joint Structural Damage at 1 Year with Rituximab in Rheumatoid Arthritis Patients with an Inadequate Response to One or More TNF Inhibitors</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-09-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-13</style></pages><abstract><style  face="normal" font="default" size="100%">Previous reports of the Reflex Study 6-month data with rituximab (RTX) indicated that this selective CD20+ B cell targeted therapy can inhibit the radiographic progression of joint structural damage in RA patients with longstanding resistance to one or more TNF inhibitors [Cohen et al. Arthritis Rheum in press).</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>